Eli Goldberger

ImmunoCellular Therapeutics, Ltd. is a clinical-stage pharmaceutical company, focused on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Its lead clinical asset is EOM613 solution, a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis. The company also develops EOM 147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of chronic and debilitating retinal diseases. The company was founded on March 20, 1987 and is headquartered in Montvale, NJ.

Part of The Sage Group plc, Payday Solutions is a private company that provides accounting services. The company is based in Louisville, KY. The company was founded by Eli Goldberger.

PDJ Components, Inc. is a private company based in Chester, NY that specializes in building wall panels, floor and roof trusses. The company's manufacturing plant is centrally located within 60 miles of NYC with access to 3 major interstate highways. The company is one of four truss plate institute inspected plants in the state and supply local lumberyards in NY, NJ, PA, and the mid-states. PDJ Components is equipped to handle both large ongoing projects and one-time small garage or residence projects. Engineered seals arrive at the job site upon delivery of trusses.

Part of EOM Pharmaceuticals Holdings, Inc., EOM Pharmaceuticals, Inc. is a privately held, clinical-stage company focused on developing novel drugs to improve the quality of life for patients with debilitating and sometimes deadly diseases. The company is based in Montvale, NJ. The company's mission is to pursue innovative approaches with small molecule therapeutics to address urgent and unmet medical needs. EOM's pipeline includes the development of the first-and-only dual-acting, broad-spectrum immunomodulator EOM613, which has the potential to treat systemic illnesses caused by intense inflammatory immune reactions, including COVID-19, influenza, and cancer cachexia. Additionally, EOM is working on an advanced formulation of EOM147, the first potential topically administered eye drop for treating retinal diseases. The company was founded by Shalom Z. Hirschman and Eli Goldberger, and Irach B. Taraporewala has been the CEO since 2020. EOM Pharmaceuticals was acquired by ImmunoCellular Therapeutics Ltd. on December 02, 2021.